Home/Filings/4/0001209191-05-043265

4//SEC Filing

OSCIENT PHARMACEUTICALS CORP 4

Accession 0001209191-05-043265

CIK 0000356830operating

View on SEC.gov Company Profile

Filed

Aug 16, 8:00 PM ET

Accepted

Aug 17, 7:15 PM ET

Size

24.2 KB

Accession

0001209191-05-043265

Insider Transaction Report

Form 4

Period: 2005-08-15

OSCIENT PHARMACEUTICALS CORPOSCI

EVNIN LUKE

10% Owner

Transactions

Sale
Common Stock
2005-08-17$2.66/sh−160,000$425,840→ 7,172,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-16$2.64/sh−150,000$396,360→ 7,332,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-15$2.61/sh−50,000$130,350→ 7,482,050 total(indirect: See footnote)

BB BIOVENTURES L P

10% Owner

Transactions

Sale
Common Stock
2005-08-16$2.64/sh−150,000$396,360→ 7,332,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-15$2.61/sh−50,000$130,350→ 7,482,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-17$2.66/sh−160,000$425,840→ 7,172,050 total(indirect: See footnote)

MPM BIOVENTURES I LP

10% Owner

Transactions

Sale
Common Stock
2005-08-16$2.64/sh−150,000$396,360→ 7,332,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-17$2.66/sh−160,000$425,840→ 7,172,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-15$2.61/sh−50,000$130,350→ 7,482,050 total(indirect: See footnote)

BAB BIO VENTURES LLP

10% Owner

Transactions

Sale
Common Stock
2005-08-16$2.64/sh−150,000$396,360→ 7,332,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-15$2.61/sh−50,000$130,350→ 7,482,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-17$2.66/sh−160,000$425,840→ 7,172,050 total(indirect: See footnote)

MPM BIOVENTURES PARALLEL FUND L P

10% Owner

Transactions

Sale
Common Stock
2005-08-15$2.61/sh−50,000$130,350→ 7,482,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-17$2.66/sh−160,000$425,840→ 7,172,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-16$2.64/sh−150,000$396,360→ 7,332,050 total(indirect: See footnote)

MPM ASSET MANAGEMENT INVESTORS 1998 LLC

10% Owner

Transactions

Sale
Common Stock
2005-08-16$2.64/sh−150,000$396,360→ 7,332,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-17$2.66/sh−160,000$425,840→ 7,172,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-15$2.61/sh−50,000$130,350→ 7,482,050 total(indirect: See footnote)

STEINMETZ MICHAEL

10% Owner

Transactions

Sale
Common Stock
2005-08-15$2.61/sh−50,000$130,350→ 7,482,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-16$2.64/sh−150,000$396,360→ 7,332,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-17$2.66/sh−160,000$425,840→ 7,172,050 total(indirect: See footnote)

BAB BIO VENTURES NV

10% Owner

Transactions

Sale
Common Stock
2005-08-15$2.61/sh−50,000$130,350→ 7,482,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-16$2.64/sh−150,000$396,360→ 7,332,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-17$2.66/sh−160,000$425,840→ 7,172,050 total(indirect: See footnote)

MPM BIO VENTURES I LLC

10% Owner

Transactions

Sale
Common Stock
2005-08-16$2.64/sh−150,000$396,360→ 7,332,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-17$2.66/sh−160,000$425,840→ 7,172,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-15$2.61/sh−50,000$130,350→ 7,482,050 total(indirect: See footnote)

GADICKE ANSBERT

10% Owner

Transactions

Sale
Common Stock
2005-08-16$2.64/sh−150,000$396,360→ 7,332,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-17$2.66/sh−160,000$425,840→ 7,172,050 total(indirect: See footnote)
Sale
Common Stock
2005-08-15$2.61/sh−50,000$130,350→ 7,482,050 total(indirect: See footnote)

Footnotes (6)

[F1]The shares were sold as follows: 43,800 by BB BioVentures L.P. ("BB BV"), 5,626 by MPM BioVentures Parallel Fund, L.P. ("BV PF") and 575 by MPM Asset Management Investors 1998 LLC ("AM 1998"). MPM BioVentures I, L.P. ("BV I") and MPM BioVentures I LLC ("BV I LLC") are the direct and indirect general partners of BV PF. BAB BioVentures L.P. ("BAB BV") and BAB BioVentures, N.V. ("BAB NV") are the direct and indirect general partners of BB BV. Luke Evnin, Ansbert Gadicke and Michael Steinmetz are the managers of BAB NV, AM 1998 and BV I LLC.
[F2]The shares are held as follows: 6,052,862 by BB BV, 777,393 by BV PF and 79,459 by AM 1998. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
[F3]The shares were sold as follows: 131,399 by BB BV, 16,876 by BV PF and 1,725 by AM 1998.
[F4]The shares are held as follows: 6,421,758 by BB BV, 825,976 by BV PF and 84,316 by AM 1998. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
[F5]The shares were sold as follows: 140,136 by BB BV, 18,024 by BV PF and 1,840 by AM 1998.
[F6]The shares are held as follows: 6,281,622 by BB BV, 807,952 by BV PF and 82,476 by AM 1998. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

Documents

1 file

4
bsf11960_bsf1le.xmlPrimary
MAIN DOCUMENT DESCRIPTION

Issuer

OSCIENT PHARMACEUTICALS CORP

CIK 0000356830

→

Entity typeoperating

IncorporatedMA

Related Parties

filerCIK 0000356830

Filing Metadata

Form type: 4
Filed: Aug 16, 8:00 PM ET
Accepted: Aug 17, 7:15 PM ET
Size: 24.2 KB

View on SEC.gov